Skip to main content
. 2022 Nov 7;12:877635. doi: 10.3389/fonc.2022.877635

Figure 4.

Figure 4

Increased MHC Class I, Class II and PD-L1 expression on CRC MSS tumors explanted from HIS-BRGS mice treated with cabozantinib, alone, and in combination with nivolumab. Mean fluorescence intensity (MFI) of MHC Class I (HLA-ABC, A), MHC Class II (HLA-DR, B) and PD-L1 (C) on mCD45-,hCD45-, EpCam+ CRC MSS tumor cells explanted from HIS-BRGS mice treated with V=untreated, N=nivolumab alone, Ca=cabozantinib alone and Ca/N=combination cabozantinib and nivolumab. Expression of HLA-ABC MHC class I is shown on both mCD45+ cells and hCD45+ cells, as negative and positive controls, respectively (A). P-values indicate ANOVA multiple comparisons with Welch’s correction: *p < 0.05, **p < 0.01, ***p < 0.001, or as indicated by number.